Emerging multidisciplinary integrative wellness company seeking to redefine mental healthcare through evidence-based medicines and novel psychedelics therapies Levitee Labs Inc. is set to start trading on the Canadian Securities Exchange (CSE) starting from July 21, 2021, under the ticker symbol ‘LVT’.
The company focuses on developing and selling high potency mushroom extract nutraceuticals and supplying equipment for cultivation of functional mushrooms.
Currently, the company runs two units namely; Sporeo Supply and Monk-E Nutraceuticals. Sporeo Supply manufactures proprietary premium mushrooms at its state-of-the-art facility in British Columbia.
On the other hand, Monk-E Nutraceuticals produces adaptogenic mushroom-based nutraceutical supplements with a core focus on mushroom extracts.
The company’s chief executive officer, Pouya Farmand, believes the timing of this listing has come in the perfect time and the company will be capitalizeing on its diversified capital base to propel its growth.
“We believe the timing could not be better for us to enter the public markets on the CSE, an exchange well recognized for innovators and disruptors. We are early in a truly exciting period in healthcare where psychedelics and mushroom-based therapies and supplements represent an opportunity to provide meaningful benefits to millions of people in need where conventional medicines have collectively failed in the areas of mental health, chronic pain and substance abuse. We are cementing cornerstones of our diversified growth strategy that will distinguish us as a market leader in multiple verticals and we look forward to sharing more developments respecting our roll-up strategy and activities with shareholders,” said the CEO.
